Targeted Treatment Plans with Adverse Event Mitigation to Improve Outcomes in Patients with BRAF-Mutated mCRC

Program Dates: July 10, 2020 - July 9, 2021
Credits: 0.5 AMA PRA Category 1 Credits™; 0.5 CNE Contact Hours

Targeted Treatment Plans with Adverse Event Mitigation to Improve Outcomes in Patients with BRAF-Mutated mCRC

Program Overview

In this module, Rona Yaeger, MD, along with Scott Kopetz, MD, PhD, course chair, will first cover strategies for modulating toxicity of targeted therapies for BRAF V600E colorectal cancer (CRC). The expert faculty will discuss best practices for improving the therapeutic index to target non-V600 BRAF mutant CRC through a discussion-based format. Recent clinical trial data, including that of the BEACON Study, will be analyzed and clinical relevance debated. Upon completion of this 30-minute module, learners will better understand optimal strategies for creating targeted treatment plans for their colorectal cancer patients.

Target Audience

Community oncologists, oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer

Learning Objective

  1. Analyze recent clinical trial data of current and emerging treatment options for the management of patients with BRAF mutated colorectal cancer


Scott Kopetz, MD, PhD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas



Rona Yaeger, MD
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer CenterNew York, New York



Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Scott Kopetz, MD, PhD Consultant/Advisor: Amal Therapeutics; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer Health; Biocartis; Boehringer Ingelheim International GmbH; Boston Biomedical, Inc.; EMD Serono Inc.; Eli Lilly and Company; Genentech Inc.; Holy Stone Healthcare Co., Ltd.; Karyopharm Therapeutics; MedImmune; Merck & Co., Inc.; Navire Pharma; Novartis Pharmaceuticals Corporation; Pierre Fabre; Roche; Redx Pharma; Symphogen

Research/Grant Support: Amgen Inc.; Array BioPharma; Biocartis; Eli Lilly and Company; EMD Serono Inc.; Genentech, Inc.; Guardant Health; MedImmune; Novartis Pharmaceuticals Corporation; Roche; Sanofi

Stock Option: MolecularMatch; Navire Pharma

Rona Yaeger, MD Consultant/Advisor: Array BioPharma; Pfizer Inc.; Natera Inc.

Research/Grant Support: Array BioPharma; Pfizer Inc.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).

Financial Support

This activity has been supported by an independent educational grant from Pfizer Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the Pre-Activity Questions
    3. Read or Review the activity content.
    4. Complete the Post-Activity Test Questions and Evaluation.
    5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web

Leave a Reply

Your email address will not be published. Required fields are marked *